APO Research
Talk to an analyst

APO RESEARCH · REPORT

Combination Vaccine and Multivalent Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Combination Vaccine and Multivalent Vaccine Industry Research Report 2026

27 December 2025145 pages

Choose your research edition.

Industry ResearchCombination Vaccine and Multivalent Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Combination Vaccine and Multivalent Vaccine Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Combination Vaccine and Multivalent Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Combination Vaccine and Multivalent Vaccine Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Combination Vaccine and Multivalent Vaccine Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Combination Vaccine and Multivalent Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Combination Vaccine and Multivalent Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Combination Vaccine and Multivalent Vaccine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Combination Vaccine and Multivalent Vaccine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Combination Vaccine and Multivalent Vaccine include BioNTech, Dynavax, Moderna, Novavax, Pfizer, Sanofi Pasteur, AIM Bio, Beijing Institute of Biological Products and Chengdu Institute of Biological Products, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Combination Vaccine and Multivalent Vaccine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Combination Vaccine and Multivalent Vaccine.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Combination Vaccine and Multivalent Vaccine Market by Company

BioNTech

Dynavax

Moderna

Novavax

Pfizer

Sanofi Pasteur

AIM Bio

Beijing Institute of Biological Products

Chengdu Institute of Biological Products

Antejin Biotechnology

GlaxoSmithKline

Kangtai Bio

Sinovac

Lanzhou Institute of Biological Products

Minhai Biological

Merck & Co.

Wanbangde Pharmaceutical

Wantai Biological

Walvax

Wuhan Institute of Biological Products

Zhifei Biological

Sino Biopharm

Combination Vaccine and Multivalent Vaccine Segment by Type

Combination Vaccine

Multivalent Vaccine

Combination Vaccine and Multivalent Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Combination Vaccine and Multivalent Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Combination Vaccine and Multivalent Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Combination Vaccine and Multivalent Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Combination Vaccine and Multivalent Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Combination Vaccine and Multivalent Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Combination Vaccine and Multivalent Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Type (2021-2026) Table 7. Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Type (2027-2032) Table 9. Global Combination Vaccine and Multivalent Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2021-2026) Table 11. Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2027-2032) Table 13. Global Combination Vaccine and Multivalent Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2021-2026) Table 16. Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2027-2032) Table 18. Combination Vaccine and Multivalent Vaccine Industry Trends Table 19. Combination Vaccine and Multivalent Vaccine Industry Drivers Table 20. Combination Vaccine and Multivalent Vaccine Industry Opportunities and Challenges Table 21. Combination Vaccine and Multivalent Vaccine Market Restraints Table 22. Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Players (2021-2026) Table 24. Global Combination Vaccine and Multivalent Vaccine Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Combination Vaccine and Multivalent Vaccine, Headquarters and Area Served Table 26. Global Combination Vaccine and Multivalent Vaccine Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Combination Vaccine and Multivalent Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032) & (US$ Million) Table 45. BioNTech Company Information Table 46. BioNTech Business Overview Table 47. BioNTech Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 48. BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio Table 49. BioNTech Recent Developments Table 50. Dynavax Company Information Table 51. Dynavax Business Overview Table 52. Dynavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 53. Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 54. Dynavax Recent Developments Table 55. Moderna Company Information Table 56. Moderna Business Overview Table 57. Moderna Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 58. Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio Table 59. Moderna Recent Developments Table 60. Novavax Company Information Table 61. Novavax Business Overview Table 62. Novavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 63. Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 64. Novavax Recent Developments Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 68. Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio Table 69. Pfizer Recent Developments Table 70. Sanofi Pasteur Company Information Table 71. Sanofi Pasteur Business Overview Table 72. Sanofi Pasteur Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 73. Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio Table 74. Sanofi Pasteur Recent Developments Table 75. AIM Bio Company Information Table 76. AIM Bio Business Overview Table 77. AIM Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 78. AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio Table 79. AIM Bio Recent Developments Table 80. Beijing Institute of Biological Products Company Information Table 81. Beijing Institute of Biological Products Business Overview Table 82. Beijing Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 83. Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 84. Beijing Institute of Biological Products Recent Developments Table 85. Chengdu Institute of Biological Products Company Information Table 86. Chengdu Institute of Biological Products Business Overview Table 87. Chengdu Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 88. Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 89. Chengdu Institute of Biological Products Recent Developments Table 90. Antejin Biotechnology Company Information Table 91. Antejin Biotechnology Business Overview Table 92. Antejin Biotechnology Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 93. Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio Table 94. Antejin Biotechnology Recent Developments Table 95. GlaxoSmithKline Company Information Table 96. GlaxoSmithKline Business Overview Table 97. GlaxoSmithKline Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 98. GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio Table 99. GlaxoSmithKline Recent Developments Table 100. Kangtai Bio Company Information Table 101. Kangtai Bio Business Overview Table 102. Kangtai Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 103. Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio Table 104. Kangtai Bio Recent Developments Table 105. Sinovac Company Information Table 106. Sinovac Business Overview Table 107. Sinovac Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 108. Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio Table 109. Sinovac Recent Developments Table 110. Lanzhou Institute of Biological Products Company Information Table 111. Lanzhou Institute of Biological Products Business Overview Table 112. Lanzhou Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 113. Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 114. Lanzhou Institute of Biological Products Recent Developments Table 115. Minhai Biological Company Information Table 116. Minhai Biological Business Overview Table 117. Minhai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 118. Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 119. Minhai Biological Recent Developments Table 120. Merck & Co. Company Information Table 121. Merck & Co. Business Overview Table 122. Merck & Co. Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 123. Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio Table 124. Merck & Co. Recent Developments Table 125. Wanbangde Pharmaceutical Company Information Table 126. Wanbangde Pharmaceutical Business Overview Table 127. Wanbangde Pharmaceutical Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 128. Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio Table 129. Wanbangde Pharmaceutical Recent Developments Table 130. Wantai Biological Company Information Table 131. Wantai Biological Business Overview Table 132. Wantai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 133. Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 134. Wantai Biological Recent Developments Table 135. Walvax Company Information Table 136. Walvax Business Overview Table 137. Walvax Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 138. Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 139. Walvax Recent Developments Table 140. Wuhan Institute of Biological Products Company Information Table 141. Wuhan Institute of Biological Products Business Overview Table 142. Wuhan Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 143. Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 144. Wuhan Institute of Biological Products Recent Developments Table 145. Zhifei Biological Company Information Table 146. Zhifei Biological Business Overview Table 147. Zhifei Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 148. Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 149. Zhifei Biological Recent Developments Table 150. Sino Biopharm Company Information Table 151. Sino Biopharm Business Overview Table 152. Sino Biopharm Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026) & (US$ Million) Table 153. Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio Table 154. Sino Biopharm Recent Developments Table 155. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Combination Vaccine and Multivalent Vaccine Product Image Figure 5. Global Combination Vaccine and Multivalent Vaccine Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Combination Vaccine and Multivalent Vaccine Market Share by Type: 2025 VS 2032 Figure 7. Combination Vaccine Product Figure 8. Multivalent Vaccine Product Figure 9. Global Combination Vaccine and Multivalent Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Combination Vaccine and Multivalent Vaccine Market Share by Application: 2025 VS 2032 Figure 11. Hospital Product Figure 12. Centers for Disease Control and Prevention Product Figure 13. Others Product Figure 14. Global Combination Vaccine and Multivalent Vaccine Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Combination Vaccine and Multivalent Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Combination Vaccine and Multivalent Vaccine Market Share by Region: 2025 VS 2032 Figure 17. Global Combination Vaccine and Multivalent Vaccine Market Share by Players in 2025 Figure 18. Global Combination Vaccine and Multivalent Vaccine Manufacturers Established Date Figure 19. Global Top 5 and 10 Combination Vaccine and Multivalent Vaccine Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 23. United States Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 26. Europe Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 28. Germany Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 38. China Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 43. Australia Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Combination Vaccine and Multivalent Vaccine Market Share by Country (2021-2032) Figure 48. Brazil Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Combination Vaccine and Multivalent Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. BioNTech Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 54. Dynavax Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 55. Moderna Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 56. Novavax Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 57. Pfizer Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 58. Sanofi Pasteur Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 59. AIM Bio Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 60. Beijing Institute of Biological Products Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 61. Chengdu Institute of Biological Products Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 62. Antejin Biotechnology Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 63. GlaxoSmithKline Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 64. Kangtai Bio Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 65. Sinovac Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 66. Lanzhou Institute of Biological Products Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 67. Minhai Biological Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 68. Merck & Co. Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 69. Wanbangde Pharmaceutical Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 70. Wantai Biological Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 71. Walvax Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 72. Wuhan Institute of Biological Products Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 73. Zhifei Biological Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026) Figure 74. Sino Biopharm Revenue Growth Rate in Combination Vaccine and Multivalent Vaccine Business (2021-2026)

Scope & coverage.

Types
  • Combination Vaccine
  • Multivalent Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • BioNTech
  • Dynavax
  • Moderna
  • Novavax
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Beijing Institute of Biological Products
  • Chengdu Institute of Biological Products
  • Antejin Biotechnology
  • GlaxoSmithKline
  • Kangtai Bio
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Minhai Biological
  • Merck & Co.
  • Wanbangde Pharmaceutical
  • Wantai Biological
  • Walvax
  • Wuhan Institute of Biological Products
  • Zhifei Biological
  • Sino Biopharm

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Combination Vaccine and Multivalent Vaccine by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Combination Vaccine
  5. 2.2.3 Multivalent Vaccine
  6. 2.3 Combination Vaccine and Multivalent Vaccine by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Hospital
  9. 2.3.3 Centers for Disease Control and Prevention
  10. 2.3.4 Others
  11. 2.4 Assumptions and Limitations
3 Combination Vaccine and Multivalent Vaccine Breakdown Data by Type
  1. 3.1 Global Combination Vaccine and Multivalent Vaccine Historic Market Size by Type (2021-2026)
  2. 3.2 Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Type (2027-2032)
4 Combination Vaccine and Multivalent Vaccine Breakdown Data by Application
  1. 4.1 Global Combination Vaccine and Multivalent Vaccine Historic Market Size by Application (2021-2026)
  2. 4.2 Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Combination Vaccine and Multivalent Vaccine Market Perspective (2021-2032)
  2. 5.2 Global Combination Vaccine and Multivalent Vaccine Growth Trends by Region
  3. 5.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Combination Vaccine and Multivalent Vaccine Historic Market Size by Region (2021-2026)
  5. 5.2.3 Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Region (2027-2032)
  6. 5.3 Combination Vaccine and Multivalent Vaccine Market Dynamics
  7. 5.3.1 Combination Vaccine and Multivalent Vaccine Industry Trends
  8. 5.3.2 Combination Vaccine and Multivalent Vaccine Market Drivers
  9. 5.3.3 Combination Vaccine and Multivalent Vaccine Market Challenges
  10. 5.3.4 Combination Vaccine and Multivalent Vaccine Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue
  2. 6.1.1 Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue (2021-2026)
  3. 6.1.2 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Combination Vaccine and Multivalent Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Combination Vaccine and Multivalent Vaccine Head Office and Area Served
  6. 6.4 Global Combination Vaccine and Multivalent Vaccine Players, Product Type & Application
  7. 6.5 Global Combination Vaccine and Multivalent Vaccine Manufacturers Established Date
  8. 6.6 Global Combination Vaccine and Multivalent Vaccine Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)
  2. 7.2 North America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  4. 7.4 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)
  2. 8.2 Europe Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  4. 8.4 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)
  2. 9.2 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)
  2. 10.2 South America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  4. 10.4 South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size (2021-2032)
  2. 11.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 BioNTech
  2. 12.1.1 BioNTech Company Information
  3. 12.1.2 BioNTech Business Overview
  4. 12.1.3 BioNTech Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  5. 12.1.4 BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio
  6. 12.1.5 BioNTech Recent Developments
  7. 12.2 Dynavax
  8. 12.2.1 Dynavax Company Information
  9. 12.2.2 Dynavax Business Overview
  10. 12.2.3 Dynavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  11. 12.2.4 Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio
  12. 12.2.5 Dynavax Recent Developments
  13. 12.3 Moderna
  14. 12.3.1 Moderna Company Information
  15. 12.3.2 Moderna Business Overview
  16. 12.3.3 Moderna Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  17. 12.3.4 Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio
  18. 12.3.5 Moderna Recent Developments
  19. 12.4 Novavax
  20. 12.4.1 Novavax Company Information
  21. 12.4.2 Novavax Business Overview
  22. 12.4.3 Novavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  23. 12.4.4 Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio
  24. 12.4.5 Novavax Recent Developments
  25. 12.5 Pfizer
  26. 12.5.1 Pfizer Company Information
  27. 12.5.2 Pfizer Business Overview
  28. 12.5.3 Pfizer Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  29. 12.5.4 Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio
  30. 12.5.5 Pfizer Recent Developments
  31. 12.6 Sanofi Pasteur
  32. 12.6.1 Sanofi Pasteur Company Information
  33. 12.6.2 Sanofi Pasteur Business Overview
  34. 12.6.3 Sanofi Pasteur Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  35. 12.6.4 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio
  36. 12.6.5 Sanofi Pasteur Recent Developments
  37. 12.7 AIM Bio
  38. 12.7.1 AIM Bio Company Information
  39. 12.7.2 AIM Bio Business Overview
  40. 12.7.3 AIM Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  41. 12.7.4 AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
  42. 12.7.5 AIM Bio Recent Developments
  43. 12.8 Beijing Institute of Biological Products
  44. 12.8.1 Beijing Institute of Biological Products Company Information
  45. 12.8.2 Beijing Institute of Biological Products Business Overview
  46. 12.8.3 Beijing Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  47. 12.8.4 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  48. 12.8.5 Beijing Institute of Biological Products Recent Developments
  49. 12.9 Chengdu Institute of Biological Products
  50. 12.9.1 Chengdu Institute of Biological Products Company Information
  51. 12.9.2 Chengdu Institute of Biological Products Business Overview
  52. 12.9.3 Chengdu Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  53. 12.9.4 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  54. 12.9.5 Chengdu Institute of Biological Products Recent Developments
  55. 12.10 Antejin Biotechnology
  56. 12.10.1 Antejin Biotechnology Company Information
  57. 12.10.2 Antejin Biotechnology Business Overview
  58. 12.10.3 Antejin Biotechnology Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  59. 12.10.4 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio
  60. 12.10.5 Antejin Biotechnology Recent Developments
  61. 12.11 GlaxoSmithKline
  62. 12.11.1 GlaxoSmithKline Company Information
  63. 12.11.2 GlaxoSmithKline Business Overview
  64. 12.11.3 GlaxoSmithKline Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  65. 12.11.4 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio
  66. 12.11.5 GlaxoSmithKline Recent Developments
  67. 12.12 Kangtai Bio
  68. 12.12.1 Kangtai Bio Company Information
  69. 12.12.2 Kangtai Bio Business Overview
  70. 12.12.3 Kangtai Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  71. 12.12.4 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
  72. 12.12.5 Kangtai Bio Recent Developments
  73. 12.13 Sinovac
  74. 12.13.1 Sinovac Company Information
  75. 12.13.2 Sinovac Business Overview
  76. 12.13.3 Sinovac Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  77. 12.13.4 Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio
  78. 12.13.5 Sinovac Recent Developments
  79. 12.14 Lanzhou Institute of Biological Products
  80. 12.14.1 Lanzhou Institute of Biological Products Company Information
  81. 12.14.2 Lanzhou Institute of Biological Products Business Overview
  82. 12.14.3 Lanzhou Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  83. 12.14.4 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  84. 12.14.5 Lanzhou Institute of Biological Products Recent Developments
  85. 12.15 Minhai Biological
  86. 12.15.1 Minhai Biological Company Information
  87. 12.15.2 Minhai Biological Business Overview
  88. 12.15.3 Minhai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  89. 12.15.4 Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  90. 12.15.5 Minhai Biological Recent Developments
  91. 12.16 Merck & Co.
  92. 12.16.1 Merck & Co. Company Information
  93. 12.16.2 Merck & Co. Business Overview
  94. 12.16.3 Merck & Co. Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  95. 12.16.4 Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio
  96. 12.16.5 Merck & Co. Recent Developments
  97. 12.17 Wanbangde Pharmaceutical
  98. 12.17.1 Wanbangde Pharmaceutical Company Information
  99. 12.17.2 Wanbangde Pharmaceutical Business Overview
  100. 12.17.3 Wanbangde Pharmaceutical Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  101. 12.17.4 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio
  102. 12.17.5 Wanbangde Pharmaceutical Recent Developments
  103. 12.18 Wantai Biological
  104. 12.18.1 Wantai Biological Company Information
  105. 12.18.2 Wantai Biological Business Overview
  106. 12.18.3 Wantai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  107. 12.18.4 Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  108. 12.18.5 Wantai Biological Recent Developments
  109. 12.19 Walvax
  110. 12.19.1 Walvax Company Information
  111. 12.19.2 Walvax Business Overview
  112. 12.19.3 Walvax Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  113. 12.19.4 Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio
  114. 12.19.5 Walvax Recent Developments
  115. 12.20 Wuhan Institute of Biological Products
  116. 12.20.1 Wuhan Institute of Biological Products Company Information
  117. 12.20.2 Wuhan Institute of Biological Products Business Overview
  118. 12.20.3 Wuhan Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  119. 12.20.4 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  120. 12.20.5 Wuhan Institute of Biological Products Recent Developments
  121. 12.21 Zhifei Biological
  122. 12.21.1 Zhifei Biological Company Information
  123. 12.21.2 Zhifei Biological Business Overview
  124. 12.21.3 Zhifei Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  125. 12.21.4 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  126. 12.21.5 Zhifei Biological Recent Developments
  127. 12.22 Sino Biopharm
  128. 12.22.1 Sino Biopharm Company Information
  129. 12.22.2 Sino Biopharm Business Overview
  130. 12.22.3 Sino Biopharm Revenue in Combination Vaccine and Multivalent Vaccine Business (2021-2026)
  131. 12.22.4 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio
  132. 12.22.5 Sino Biopharm Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst